GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Debt-to-Revenue

Satellos Bioscience (TSX:MSCL) Debt-to-Revenue : N/A (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Satellos Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$0.00 Mil. Satellos Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$0.00 Mil. Satellos Bioscience's annualized Revenue for the quarter that ended in Mar. 2024 was C$0.00 Mil.


Satellos Bioscience Debt-to-Revenue Historical Data

The historical data trend for Satellos Bioscience's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience Debt-to-Revenue Chart

Satellos Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
N/A N/A N/A N/A

Satellos Bioscience Quarterly Data
Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Satellos Bioscience's Debt-to-Revenue

For the Biotechnology subindustry, Satellos Bioscience's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Satellos Bioscience's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Satellos Bioscience's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Satellos Bioscience's Debt-to-Revenue falls into.



Satellos Bioscience Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Satellos Bioscience's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Satellos Bioscience's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Satellos Bioscience Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Satellos Bioscience (TSX:MSCL) Business Description

Traded in Other Exchanges
Address
65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5
Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience (TSX:MSCL) Headlines

No Headlines